Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Roche strikes $5.3 billion amylin deal

Roche strikes $5.3 billion amylin deal News News in brief compared with knocking down other MMR recruits RNase H to cut at a single-nucleotide components, such as MSH2 or PMS2, so the polymorphism (rs362273) found in mHTT company has spent the several years iden- exon 57 that is absent in the wild-type allele. Roche strikes tifying allosteric inhibitors that potently Last July, a phase 1b/2 trial readout of WVE- bind sites outside MSH3’s ATP pocket with 003 showed a 46% reduction in cerebrospi- $5.3 billion high selectivity. According to Reynolds, the nal fluid mHTT compared with placebo. The company is on track to initiate Investigational treatment preserved wild-type HTT and was amylin deal New Drug application-enabling studies later generally safe and well tolerated. According to this year. CEO Paul Bolno, “The next milestone is getting oche is gaining access to petrelintide, a Harness Therapeutics, by contrast, is going the phase 2/3 registrational study initiated in potentially best-in-class amylin analog, after FAN1, a DNA repair enzyme shown to the second half of this year.” Rpaying Copenhagen-based Zealand retard somatic expansion; it has the strongest Therapies using small interfering RNA Pharma $1.65 billion up front and up to protective signals from genome-wide asso- (siRNA) to lower HTT http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Biotechnology Springer Journals

Roche strikes $5.3 billion amylin deal

Nature Biotechnology , Volume 43 (4) – Apr 1, 2025
Download PDF
1 page

Roche strikes $5.3 billion amylin deal

Abstract

News News in brief compared with knocking down other MMR recruits RNase H to cut at a single-nucleotide components, such as MSH2 or PMS2, so the polymorphism (rs362273) found in mHTT company has spent the several years iden- exon 57 that is absent in the wild-type allele. Roche strikes tifying allosteric inhibitors that potently Last July, a phase 1b/2 trial readout of WVE- bind sites outside MSH3’s ATP pocket with 003 showed a 46% reduction in cerebrospi- $5.3 billion high selectivity....
Loading next page...
 
/lp/springer-journals/roche-strikes-5-3-billion-amylin-deal-027eLZ0miq

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer Nature America, Inc. 2025
ISSN
1087-0156
eISSN
1546-1696
DOI
10.1038/s41587-025-02657-1
Publisher site
See Article on Publisher Site

Abstract

News News in brief compared with knocking down other MMR recruits RNase H to cut at a single-nucleotide components, such as MSH2 or PMS2, so the polymorphism (rs362273) found in mHTT company has spent the several years iden- exon 57 that is absent in the wild-type allele. Roche strikes tifying allosteric inhibitors that potently Last July, a phase 1b/2 trial readout of WVE- bind sites outside MSH3’s ATP pocket with 003 showed a 46% reduction in cerebrospi- $5.3 billion high selectivity. According to Reynolds, the nal fluid mHTT compared with placebo. The company is on track to initiate Investigational treatment preserved wild-type HTT and was amylin deal New Drug application-enabling studies later generally safe and well tolerated. According to this year. CEO Paul Bolno, “The next milestone is getting oche is gaining access to petrelintide, a Harness Therapeutics, by contrast, is going the phase 2/3 registrational study initiated in potentially best-in-class amylin analog, after FAN1, a DNA repair enzyme shown to the second half of this year.” Rpaying Copenhagen-based Zealand retard somatic expansion; it has the strongest Therapies using small interfering RNA Pharma $1.65 billion up front and up to protective signals from genome-wide asso- (siRNA) to lower HTT

Journal

Nature Biotechnology – Springer Journals

Published: Apr 1, 2025

There are no references for this article.